Risk-prediction models for intravenous immunoglobulin resistance in Kawasaki disease : Risk-of-Bias Assessment using PROBAST
© 2023. The Author(s)..
BACKGROUND: The prediction model of intravenous immunoglobulin (IVIG) resistance in Kawasaki disease can calculate the probability of IVIG resistance and provide a basis for clinical decision-making. We aim to assess the quality of these models developed in the children with Kawasaki disease.
METHODS: Studies of prediction models for IVIG-resistant Kawasaki disease were identified through searches in the PubMed, Web of Science, and Embase databases. Two investigators independently performed literature screening, data extraction, quality evaluation, and discrepancies were settled by a statistician. The checklist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) was used for data extraction, and the prediction models were evaluated using the Prediction Model Risk of Bias Assessment Tool (PROBAST).
RESULTS: Seventeen studies meeting the selection criteria were included in the qualitative analysis. The top three predictors were neutrophil measurements (peripheral neutrophil count and neutrophil %), serum albumin level, and C-reactive protein (CRP) level. The reported area under the curve (AUC) values for the developed models ranged from 0.672 (95% confidence interval [CI]: 0.631-0.712) to 0.891 (95% CI: 0.837-0.945); The studies showed a high risk of bias (ROB) for modeling techniques, yielding a high overall ROB.
CONCLUSION: IVIG resistance models for Kawasaki disease showed high ROB. An emphasis on improving their quality can provide high-quality evidence for clinical practice.
IMPACT STATEMENT: This study systematically evaluated the risk of bias (ROB) of existing prediction models for intravenous immunoglobulin (IVIG) resistance in Kawasaki disease to provide guidance for future model development meeting clinical expectations. This is the first study to systematically evaluate the ROB of IVIG resistance in Kawasaki disease by using PROBAST. ROB may reduce model performance in different populations. Future prediction models should account for this problem, and PROBAST can help improve the methodological quality and applicability of prediction model development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:94 |
|---|---|
| Enthalten in: |
Pediatric research - 94(2023), 3 vom: 24. Sept., Seite 1125-1135 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Shuhui [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immunoglobulins, Intravenous |
|---|
| Anmerkungen: |
Date Completed 24.08.2023 Date Revised 18.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41390-023-02558-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354695266 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354695266 | ||
| 003 | DE-627 | ||
| 005 | 20231226062753.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41390-023-02558-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1182.xml |
| 035 | |a (DE-627)NLM354695266 | ||
| 035 | |a (NLM)36964445 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Shuhui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk-prediction models for intravenous immunoglobulin resistance in Kawasaki disease |b Risk-of-Bias Assessment using PROBAST |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.08.2023 | ||
| 500 | |a Date Revised 18.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: The prediction model of intravenous immunoglobulin (IVIG) resistance in Kawasaki disease can calculate the probability of IVIG resistance and provide a basis for clinical decision-making. We aim to assess the quality of these models developed in the children with Kawasaki disease | ||
| 520 | |a METHODS: Studies of prediction models for IVIG-resistant Kawasaki disease were identified through searches in the PubMed, Web of Science, and Embase databases. Two investigators independently performed literature screening, data extraction, quality evaluation, and discrepancies were settled by a statistician. The checklist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) was used for data extraction, and the prediction models were evaluated using the Prediction Model Risk of Bias Assessment Tool (PROBAST) | ||
| 520 | |a RESULTS: Seventeen studies meeting the selection criteria were included in the qualitative analysis. The top three predictors were neutrophil measurements (peripheral neutrophil count and neutrophil %), serum albumin level, and C-reactive protein (CRP) level. The reported area under the curve (AUC) values for the developed models ranged from 0.672 (95% confidence interval [CI]: 0.631-0.712) to 0.891 (95% CI: 0.837-0.945); The studies showed a high risk of bias (ROB) for modeling techniques, yielding a high overall ROB | ||
| 520 | |a CONCLUSION: IVIG resistance models for Kawasaki disease showed high ROB. An emphasis on improving their quality can provide high-quality evidence for clinical practice | ||
| 520 | |a IMPACT STATEMENT: This study systematically evaluated the risk of bias (ROB) of existing prediction models for intravenous immunoglobulin (IVIG) resistance in Kawasaki disease to provide guidance for future model development meeting clinical expectations. This is the first study to systematically evaluate the ROB of IVIG resistance in Kawasaki disease by using PROBAST. ROB may reduce model performance in different populations. Future prediction models should account for this problem, and PROBAST can help improve the methodological quality and applicability of prediction model development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 700 | 1 | |a Huang, Hongbiao |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Miao |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Qiuqin |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Weiguo |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Yunjia |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xuan |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Guanghui |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yiming |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yueping |e verfasserin |4 aut | |
| 700 | 1 | |a Lv, Haitao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric research |d 1967 |g 94(2023), 3 vom: 24. Sept., Seite 1125-1135 |w (DE-627)NLM000008672 |x 1530-0447 |7 nnns |
| 773 | 1 | 8 | |g volume:94 |g year:2023 |g number:3 |g day:24 |g month:09 |g pages:1125-1135 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41390-023-02558-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 94 |j 2023 |e 3 |b 24 |c 09 |h 1125-1135 | ||